ArticleClinical and experimental nephrology2025
Effects of magnetic field therapy (AT-04) on pain reduction during arteriovenous fistula puncture in hemodialysis.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPain from arteriovenous fistula puncture significantly affects the quality of life of patients undergoing hemodialysis. AT-04 was designed to alleviate this pain using magnetic stimulation, which is anticipated to be beneficial for managing pain across different conditions. However, limited research exists on the effectiveness of AT-04 in diminishing the pain related to arteriovenous fistula puncture in hemodialysis patients.
methodsBetween July and August 2024, we enrolled 14 outpatient maintenance hemodialysis patients at Tokyu Hospital who had given informed consent. AT-04 was administered before arteriovenous fistula puncture. We assessed the pain intensity of the puncture using the Visual Analog Scale (VAS) before the application of AT-04, as well as at one and four weeks afterward. We observed changes in puncture pain levels before and after the AT-04 application.
resultsThe participants had an average age of 80 years (IQR, 74-85) and a mean dialysis duration of 5.8 years (IQR, 1.0-8.9). Lidocaine tape was utilized by 71.4% of participants, painkillers by 7.1%, and 28.6% used sleeping pills, with none taking antidepressants. The median VAS score before starting AT-04 was 40.5 (IQR, 23.5-55.5). One week after starting AT-04, the median VAS score dropped to 27.0 (IQR, 4.5-32.8), and four weeks later, it further decreased to 16.5 (IQR, 5.0-38.8). These decreases were statistically significant compared to the pre-treatment VAS score (one week after p = 0.0057, four weeks after p = 0.0076).
conclusionThe AT-04 device, which uses alternating magnetic field therapy, significantly alleviated pain from arteriovenous fistula puncture in hemodialysis patients.
Indexed as
Identifiers
40140208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.